Form 4: MindMed Executive Miri Halperin Wernli Exercises Stock Options and Sells Shares
SEC Form 4 Filing
Miri Halperin Wernli, Executive President of Mind Medicine (MindMed) Inc., exercised stock options and sold shares to cover the exercise price and tax obligations.
Summary
- On August 21, 2024, Miri Halperin Wernli, Executive President of Mind Medicine (MindMed) Inc., exercised stock options to acquire 50,000 common shares at a price of $3.70 per share.
- The exercised options were set to expire on February 27, 2025.
- To cover the exercise price and tax withholding, Wernli engaged in a 'net exercise' where MindMed withheld 32,595 shares.
- Wernli received 17,405 common shares after the withholding.
- The price used for the withholding calculation was $6.17 per share, representing the closing price on August 20, 2024.
- Following these transactions, Wernli directly owns 202,405 common shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports the execution of stock options and a subsequent sale of shares to cover costs, which is a routine financial transaction.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be scrutinized by investors for insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Net exercises of stock options are a common practice among executives to cover the cost of exercising options and associated tax liabilities.
- The specifics of the option grants (vesting schedule, exercise price, expiration date) are typical components of executive compensation packages designed to align management's interests with those of shareholders.
- Comparable companies in the biotech/pharmaceutical space also utilize stock options as part of their compensation strategy.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the issuance of new shares and a subsequent sale on the open market.
- The executive benefits from the stock option exercise, aligning their interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| February 27, 2020 | Date of grant for the stock options that were exercised. |
| August 20, 2024 | Closing price of $6.17 used for the net exercise calculation. |
| August 21, 2024 | Date of the stock option exercise and share sale. |
| August 22, 2024 | Date of signature for the Form 4 filing. |
| February 27, 2025 | Original expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.